Fri Sep 13 15:36:00 UTC 2024: ## New Immunotherapies and Antibody Drug Conjugates Show Promise in Lung Cancer Treatment

**San Diego, CA – September 10, 2024** – At the World Conference on Lung Cancer, Dr. Christian Rolfo, of the James Comprehensive Cancer Center at The Ohio State University, presented a comprehensive overview of emerging treatment options for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). His presentation focused on six different treatment options under development, including immunotherapies and antibody drug conjugates.

**Immunotherapy Updates:**

* **Tislelizumab (Tevimbra) and Sitravatinib:** While initial findings from the SAFFRON-301 trial showed a longer progression-free survival (PFS) compared to chemotherapy, the study was terminated due to serious pulmonary hemorrhage-related toxicity.
* **Pembrolizumab and Itacitinib:** This combination therapy demonstrated a median PFS of 15.6 months in a phase 2 study for metastatic NSCLC, with longer PFS observed in patients with higher PD-L1 expression.
* **N-803 (Anktiva):** This immunotherapy showed no significant differences in overall survival across various cohorts, including those treated with prior checkpoint inhibitors.

**Antibody Drug Conjugates for SCLC:**

* **Ifinatamab Deruxtecan (I-DXd):** This treatment showed a higher overall response rate (ORR) at the higher dose of 12 mg/kg every 3 weeks compared to the lower dose of 8 mg/kg. PFS and OS were also longer with the higher dose.
* **HS-20093:** This B7-H3-directed antibody drug conjugate demonstrated an ORR of 61.3% at 8 mg/kg and 50% at 10 mg/kg every 3 weeks. It showed promise for patients previously treated with platinum-based chemotherapy and immunotherapy.
* **Sacituzumab Govitecan:** This treatment achieved an ORR of 41.9% in the TROPiCS-03 trial, with a median duration of response of 4.7 months. It showed particular benefit in patients with platinum-resistant disease.

Dr. Rolfo concluded his presentation highlighting the promising potential of novel combinations such as JAK2 inhibitors and PD-1 in first-line treatment, as well as the use of superagonist interleukin 15 with checkpoint inhibitors in pre-treated populations. He emphasized the need for continued research and development of these innovative therapies to improve outcomes for lung cancer patients.

Read More